171 related articles for article (PubMed ID: 27470571)
61. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
62. Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
Wang Q; Zhao W; Wu G
Eur J Cancer Prev; 2009 Nov; 18(6):510-7. PubMed ID: 19687742
[TBL] [Abstract][Full Text] [Related]
63. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer.
Herr D; Rodewald M; Fraser HM; Hack G; Konrad R; Kreienberg R; Wulff C
Gynecol Oncol; 2008 Jun; 109(3):418-25. PubMed ID: 18395779
[TBL] [Abstract][Full Text] [Related]
64. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis.
Xie Y; Sheng W; Xiang J; Ye Z; Yang J
Cancer Invest; 2010 Jul; 28(6):598-607. PubMed ID: 20210523
[TBL] [Abstract][Full Text] [Related]
65. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
Zhao Y; Chen X; Cai L; Yang Y; Sui G; Fu S
J Cell Physiol; 2010 Oct; 225(1):168-73. PubMed ID: 20458733
[TBL] [Abstract][Full Text] [Related]
66. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor.
Usui T; Sugisaki K; Iriyama A; Yokoo S; Yamagami S; Nagai N; Ishida S; Amano S
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4370-6. PubMed ID: 18829859
[TBL] [Abstract][Full Text] [Related]
68. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
Arafat HA; Gong Q; Chipitsyna G; Rizvi A; Saa CT; Yeo CJ
J Am Coll Surg; 2007 May; 204(5):996-1005; discussion 1005-6. PubMed ID: 17481528
[TBL] [Abstract][Full Text] [Related]
69. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
70. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart.
Siddiqui AJ; Mansson-Broberg A; Gustafsson T; Grinnemo KH; Dellgren G; Hao X; Fischer H; Sylvén C
Am J Hypertens; 2005 Oct; 18(10):1347-52. PubMed ID: 16202860
[TBL] [Abstract][Full Text] [Related]
71. Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.
Hao CY
J Gastroenterol Hepatol; 2011 Jan; 26(1):4-6. PubMed ID: 21175786
[No Abstract] [Full Text] [Related]
72. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
73. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
[TBL] [Abstract][Full Text] [Related]
74. [Inhibitory effects of ampelopsin on angiogenesis].
Luo GQ; Zeng S; Liu DY
Zhong Yao Cai; 2006 Feb; 29(2):146-50. PubMed ID: 16617784
[TBL] [Abstract][Full Text] [Related]
75. Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models.
Feng LL; Liu BX; Zhong JY; Sun LB; Yu HS
Asian Pac J Cancer Prev; 2014; 15(2):737-41. PubMed ID: 24568488
[TBL] [Abstract][Full Text] [Related]
76. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.
Enomoto H; Tao L; Eguchi R; Sato A; Honda M; Kaneko S; Iwata Y; Nishikawa H; Imanishi H; Iijima H; Tsujimura T; Nishiguchi S
Sci Rep; 2017 Sep; 7(1):12189. PubMed ID: 28939881
[TBL] [Abstract][Full Text] [Related]
77. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.
Chen J; Liu J; Xu B; Cao Y; Liang X; Wu F; Shen X; Ma X; Liu J
Toxicol Appl Pharmacol; 2022 Mar; 438():115911. PubMed ID: 35143806
[TBL] [Abstract][Full Text] [Related]
78. The antiangiogenic effects of tyroservatide on animal models of hepatocellular carcinoma.
Zhang N; Wang L; Liang Y; Zhao YM; Xue Q; Wu WZ; Sun HC; Fan J; Tang ZY
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1447-53. PubMed ID: 19399517
[TBL] [Abstract][Full Text] [Related]
79. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
80. [Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice].
Liu L; Chen BA; Qin SK
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Jan; 31(1):67-72. PubMed ID: 21434348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
